Vertex Energy (VTNR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

Now, it’s worth noting Stock Advisor's total average return is 1,061% — a market-crushing outperformance compared to 192% for ...

Vertex Pharmaceuticals has built a billion-dollar cystic fibrosis business over time. But the company today may be preparing for a new era of growth, thanks to the strength of its pipeline. Vertex ...

Loomis Sayles, an investment management company, released its “Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned ...

As of now, enterprises can access Anthropic's Claude models in India via Amazon Bedrock and Google Cloud Vertex AI, the ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). The Boston-based Big Biotech’s sodium channel inhibitor VX-993 failed to outpace ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Vertex's Phase 2 study of suzetrigine met its primary endpoint, reducing pain on the NPRS by -2.02 at Week 12. Post-hoc analysis revealed variability in placebo response, highlighting trial design ...

When Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that what was then a sea of parking lots could be a booming business district, and galvanized a wave of ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is trading near a record high after climbing about 20% so far this year, and delivering a triple-digit gain over three years. So, you may be a bit hesitant about ...